FLT3 and Thrombocytopenia: His AML was characterized by WT1 overexpression, NPM1 type A mutation, FLT3-ITD mutation and a normal karyotype, placing him in the intermediate-risk category according to the 2022 European LeukemiaNet (ELN) guidelines.17 Initial presentation included anaemia, thrombocytopaenia and hyperleukocytosis (56 × 106/L blasts).